Intravenous and oral copper kinetics, biodistribution and dosimetry in healthy humans studied by [64Cu]copper PET/CT
Tóm tắt
Copper is essential for enzymatic processes throughout the body. [64Cu]copper (64Cu) positron emission tomography (PET) has been investigated as a diagnostic tool for certain malignancies, but has not yet been used to study copper homeostasis in humans. In this study, we determined the hepatic removal kinetics, biodistribution and radiation dosimetry of 64Cu in healthy humans by both intravenous and oral administration. Six healthy participants underwent PET/CT studies with intravenous or oral administration of 64Cu. A 90 min dynamic PET/CT scan of the liver was followed by three whole-body PET/CT scans at 1.5, 6, and 20 h after tracer administration. PET data were used for estimation of hepatic kinetics, biodistribution, effective doses, and absorbed doses for critical organs. After intravenous administration, 64Cu uptake was highest in the liver, intestinal walls and pancreas; the gender-averaged effective dose was 62 ± 5 μSv/MBq (mean ± SD). After oral administration, 64Cu was almost exclusively taken up by the liver while leaving a significant amount of radiotracer in the gastrointestinal lumen, resulting in an effective dose of 113 ± 1 μSv/MBq. Excretion of 64Cu in urine and faeces after intravenous administration was negligible. Hepatic removal kinetics showed that the clearance of 64Cu from blood was 0.10 ± 0.02 mL blood/min/mL liver tissue, and the rate constant for excretion into bile or blood was 0.003 ± 0.002 min− 1. 64Cu biodistribution and radiation dosimetry are influenced by the manner of tracer administration with high uptake by the liver, intestinal walls, and pancreas after intravenous administration, while after oral administration, 64Cu is rapidly absorbed from the gastrointestinal tract and deposited primarily in the liver. Administration of 50 MBq 64Cu yielded images of high quality for both administration forms with radiation doses of approximately 3.1 and 5.7 mSv, respectively, allowing for sequential studies in humans. EudraCT no. 2016–001975-59. Registration date: 19/09/2016.
Tài liệu tham khảo
Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson's disease. Lancet (London, England). 2007;369:397–408. https://doi.org/10.1016/s0140-6736(07)60196-2.
Alda JO, Garay R. Chloride (or bicarbonate)-dependent copper uptake through the anion exchanger in human red blood cells. Am J Phys. 1990;259:C570–6. https://doi.org/10.1152/ajpcell.1990.259.4.C570.
Avila-Rodriguez MA, Rios C, Carrasco-Hernandez J, Manrique-Arias JC, Martinez-Hernandez R, Garcia-Perez FO, et al. Biodistribution and radiation dosimetry of [(64)Cu]copper dichloride: first-in-human study in healthy volunteers. EJNMMI Res. 2017;7:98. https://doi.org/10.1186/s13550-017-0346-4.
ICRP. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP. 2002;32:5–265. http://www.icrp.org/publication.asp?id=icrp%20publication%2089.
ICRP. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37:1–332. https://doi.org/10.1016/j.icrp.2007.10.003.
Capasso E, Durzu S, Piras S, Zandieh S, Knoll P, Haug A, et al. Role of (64) CuCl 2 PET/CT in staging of prostate cancer. Ann Nucl Med. 2015;29:482–8. https://doi.org/10.1007/s12149-015-0968-4.
Conti M, Eriksson L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys. 2016;3:8. https://doi.org/10.1186/s40658-016-0144-5.
Cousins RJ. Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. Physiol Rev. 1985;65:238–309. https://doi.org/10.1152/physrev.1985.65.2.238.
Czlonkowska A, Rodo M, Wierzchowska-Ciok A, Smolinski L, Litwin T. Accuracy of the radioactive copper incorporation test in the diagnosis of Wilson disease. Liver Int. 2018;38:1860–6. https://doi.org/10.1111/liv.13715.
Gunther K, Lossner V, Lossner J, Biesold D. The kinetics of copper uptake by the liver in Wilson's disease studied by a whole-body counter and a double labelling technique. Eur Neurol. 1975;13:385–94. https://doi.org/10.1159/000114694.
Gupta A, Lutsenko S. Human copper transporters: mechanism, role in human diseases and therapeutic potential. Future Med Chem. 2009;1:1125–42. https://doi.org/10.4155/fmc.09.84.
Harvey LJ, Dainty JR, Hollands WJ, Bull VJ, Beattie JH, Venelinov TI, et al. Use of mathematical modeling to study copper metabolism in humans. Am J Clin Nutr. 2005;81:807–13. https://doi.org/10.1093/ajcn/81.4.807.
Janssens AR, Van den Hamer CJ. Kinetics of 64Copper in primary biliary cirrhosis. Hepatology (Baltimore, Md). 1982;2:822–7. https://doi.org/10.1002/hep.1840020614.
Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740–7. https://doi.org/10.1038/jcbfm.1990.127.
Marceau N, Aspin N. Distribution of ceruloplasmin- ceruloplasmin-bound 67 Cu in the rat. Am J Phys. 1972;222:106–10. https://doi.org/10.1152/ajplegacy.1972.222.1.106.
Matte JJ, Girard CL, Guay F. Intestinal fate of dietary zinc and copper: postprandial net fluxes of these trace elements in portal vein of pigs. J Trace Elements Med Biol. 2017;44:65–70. https://doi.org/10.1016/j.jtemb.2017.06.003.
McParland BJ. Nuclear medicine radiation dosimetry. Advanced theoretical principles. London: Springer; 2010. p. 568.
Munk OL, Bass L, Roelsgaard K, Bender D, Hansen SB, Keiding S. Liver kinetics of glucose analogs measured in pigs by PET: importance of dual-input blood sampling. J Nucl Med. 2001;42:795–801.
Nyasae L, Bustos R, Braiterman L, Eipper B, Hubbard A. Dynamics of endogenous ATP7A (Menkes protein) in intestinal epithelial cells: copper-dependent redistribution between two intracellular sites. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1181–94. https://doi.org/10.1152/ajpgi.00472.2006.
Ørntoft NW, Munk OL, Frisch K, Ott P, Keiding S, Sørensen M. Hepatobiliary transport kinetics of the conjugated bile acid tracer 11C-CSar quantified in healthy humans and patients by positron emission tomography. J Hepatol. 2017;67:321–7. https://doi.org/10.1016/j.jhep.2017.02.023.
Panichelli P, Villano C, Cistaro A, Bruno A, Barbato F, Piccardo A, et al. Imaging of brain tumors with copper-64 chloride: early experience and results. Cancer Biother Radiopharm. 2016;31:159–67. https://doi.org/10.1089/cbr.2016.2028.
Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985;5:584–90. https://doi.org/10.1038/jcbfm.1985.87.
Peng F, Lu X, Janisse J, Muzik O, Shields AF. PET of human prostate cancer xenografts in mice with increased uptake of 64CuCl2. J Nucl Med. 2006;47:1649–52.
Peng F, Lutsenko S, Sun X, Muzik O. Imaging copper metabolism imbalance in Atp7b (−/−) knockout mouse model of Wilson's disease with PET-CT and orally administered 64CuCl2. Mol Imaging Biol. 2012;14:600–7. https://doi.org/10.1007/s11307-011-0532-0.
Piccardo A, Paparo F, Puntoni M, Righi S, Bottoni G, Bacigalupo L, et al. (64)CuCl2 PET/CT in prostate cancer relapse. Journal of nuclear medicine : official publication. Soc Nucl Med. 2018;59:444–51. https://doi.org/10.2967/jnumed.117.195628.
Stabin MG, Siegel JA. RADAR dose estimate report: A compendium of radiopharmaceutical dose estimates based on OLINDA/EXM version 2.0. J Nucl Med. 2018;59:154–60. https://doi.org/10.2967/jnumed.117.196261.
Sternlieb I. Copper and the liver. Gastroenterology. 1980;78:1615–28.
Sternlieb I, Scheinberg IH. Radiocopper in diagnosing liver disease. Semin Nucl Med. 1972;2:176–88.
Tapiero H, Townsend DM, Tew KD. Trace elements in human physiology and pathology. Copper. Biomed Pharmacother. 2003;57:386–98. https://doi.org/10.1016/s0753-3322(03)00012-x.
Turnlund JR, Keyes WR, Anderson HL, Acord LL. Copper absorption and retention in young men at three levels of dietary copper by use of the stable isotope 65Cu. Am J Clin Nutr. 1989;49:870–8. https://doi.org/10.1093/ajcn/49.5.870.
Wachsmann J, Peng F. Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma. World J Gastroenterol. 2016;22:221–31. https://doi.org/10.3748/wjg.v22.i1.221.
Wapnir RA. Copper absorption and bioavailability. Am J Clin Nutr. 1998;67:1054s–60s. https://doi.org/10.1093/ajcn/67.5.1054S.
Winge DR. Normal physiology of copper metabolism. Semin Liver Dis. 1984;4:239–51. https://doi.org/10.1055/s-2008-1041774.
Zhou B, Gitschier J. hCTR1: a human gene for copper uptake identified by complementation in yeast. Proc Natl Acad Sci U S A. 1997;94:7481–6. https://doi.org/10.1073/pnas.94.14.7481.
Zhou Y, Li J, Xu X, Zhao M, Zhang B, Deng S, et al. (64)Cu-based Radiopharmaceuticals in Molecular Imaging. Technol Cancer Res Treat. 2019;18:1533033819830758. https://doi.org/10.1177/1533033819830758.